Evidence map›Paper›PMID 36188717›Full record

ArticleWorld journal of gastroenterology2022

Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax.

Sarah Romero, Andy Kh Lim, Gurpreet Singh, Chamani Kodikara, Rachel Shingaki-Wells, Lynna Chen, Samuel Hui, Marcus Robertson

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. TIPS: indications, Contraindications, and Evaluation.Current gastroenterology reports · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah RomeroDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia. s.romero.md@gmail.com.
Andy Kh LimDepartment of General Medicine, School of Clinical Sciences, Monash University, Clayton 3168, Victoria, Australia.
Gurpreet SinghGastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia.
Chamani KodikaraDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia.
Rachel Shingaki-WellsDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia.
Lynna ChenGastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia.
Samuel HuiDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia.
Marcus RobertsonDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic hydrothorax (HH) is an uncommon and difficult-to-manage complication of cirrhosis with limited treatment options.

aimTo define the clinical outcomes of patients presenting with HH managed with current standards-of-care and to identify factors associated with mortality.

methodsCirrhotic patients with HH presenting to 3 tertiary centres from 2010 to 2018 were retrospectively identified. HH was defined as pleural effusion in the absence of cardiopulmonary disease. The primary outcomes were overall and transplant-free survival at 12-mo after the index admission. Cox proportional hazards analysis was used to determine factors associated with the primary outcomes.

resultsOverall, 84 patients were included (mean age, 58 years) with a mean model for end-stage liver disease score of 29. Management with diuretics alone achieved long-term resolution of HH in only 12% patients. At least one thoracocentesis was performed in 73.8% patients, transjugular intrahepatic portosystemic shunt insertion in 11.9% patients and 33% patients received liver transplantation within 12-mo of index admission. Overall patient survival and transplant-free survival at 12 mo were 68% and 41% respectively. At multivariable analysis, current smoking [hazard ratio (HR) = 8.65, 95% confidence interval (CI): 3.43-21.9,

conclusionCirrhotic patients with HH are a challenging population with a poor 12-mo survival despite current treatments. Current smoking and episodes of AKI are potential modifiable factors affecting survival. HH is often refractory of diuretic therapy and transplant assessment should be considered in all cases.

Indexed as

Acute Kidney InjuryEnd Stage Liver DiseaseHydrothoraxPortasystemic Shunt, Transjugular IntrahepaticDiureticsHumansLiver CirrhosisMiddle AgedRetrospective StudiesSeverity of Illness IndexTreatment OutcomeDiureticsAscitesCirrhosisHepatic hydrothoraxLiver transplantationPortal hypertension

Identifiers

PMID36188717
PMCPMC9516676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.